Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: Approaches, strategies, risks and benefits

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 4, 2005, Pages 571-590

  Olshansky, Brian ^a   Guo, Hongsheng ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Ablation; Anticoagulation; Atrial fibrillation; Cardioversion; Heparin; Low molecular weight heparin; Stroke; Surgical procedure; Thromboembolism; Warfarin; Ximelagatran

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; IDRAPARINUX; IRBESARTAN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; RAZAXABAN; TRIFLUSAL; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEPATITIS; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; LIVER DYSFUNCTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SINUS RHYTHM; STROKE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; CEREBROVASCULAR ACCIDENT; ELECTRIC COUNTERSHOCK; HEPARIN; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 23244446182     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.3.4.571     Document Type: Review

References (189)

1. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation). Developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 104, 2118-2150 (2001).
2. Levy S, Maarek M, Coumel P et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 99, 3028-3035 (1999).
3. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: strategies to control, combat, and cure. Lancet 359, 593-603 (2002).
4. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc. Res. 54, 230-246 (2002).
5. Kamp O, Verhorst PM, Welling RC, Visser CA. Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation. Eur. Heart J. 20, 979-985 (1999).
6. O'Neill PG, Puleo PR, Bolli R, Rokey R. Return of atrial mechanical function following electrical conversion of atrial dysrhythmias. Am. Heart J. 120, 353-359 (1990).
7. Louie EK, Liu D, Reynertson SI et al. 'Stunning' of the left atrium after spontaneous conversion of atrial fibrillation to sinus rhythm: demonstration by transesophageal Doppler techniques in a canine model. J. Am. Coll. Cardiol. 32, 2081-2086 (1998).
8. Grimm RA, Stewart WJ, Arheart K, Thomas JD, Klein AL. Left atrial appendage 'stunning' after electrical cardioversion of atrial flutter: an attenuated response compared with atrial fibrillation as the mechanism for lower susceptibility to thromboembolic events. J. Am. Coll. Cardiol. 29, 582-589 (1997).
9. Sparks PB, Jayaprakash S, Vohra JK et al. Left atrial 'stunning' following radiofrequency catheter ablation of chronic atrial flutter. J. Am. Coll. Cardiol. 32, 468-475 (1998).
10. Sparks PB, Jayaprakash S, Mond HG, Vohra JK, Grigg LE, Kalman JM. Left atrial mechanical function after brief duration atrial fibrillation. J. Am. Coll. Cardiol. 33, 342-349 (1999).
11. Sparks PB, Kulkarni R, Vohra JK et al. Effect of direct current shocks on left atrial mechanical function in patients with structural heart disease. J. Am. Coll. Cardiol. 31, 1395-1399 (1998).
12. Khan IA. Atrial stunning: determinants and cellular mechanisms. Am. Heart J. 145, 787-794 (2003).
13. Oltrona L, Broccolino M, Merlini PA, Spinola A, Pezzano A, Mannucci PM. Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. Circulation 95, 2003-2006 (1997).
14. Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet 346, 1313-1314 (1995).
15. Lip GY. Hypercoagulability and haemodynamic abnormalities in atrial fibrillation. Heart 77, 395-396 (1997).
16. Lip GY, Rumley A, Dunn FG, Lowe GD. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int. J. Cardiol. 51, 245-251 (1995).
17. Li-Saw-Hee FL, Blann AD, Lip GY. Effect of degree of blood pressure on the hypercoagulable state in chronic atrial fibrillation. Am. J. Cardiol. 86, 795-797 (2000).
18. Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke 33, 2187-2191 (2002).
19. Kamath S, Blann AD, Chin BS et al. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur. Heart J. 23, 1788-1795 (2002).
20. Mahe I, Drouet L, Chassany O et al. D-dimer: a characteristic of the coagulation state of each patient with chronic atrial fibrillation. Thromb. Res. 107, 1-6 (2002).
21. Gokce M, Ucar F, Kucukosmanoglu M, Erdogan T, Kaplan S. Factor V Leiden mutation and its relation to left atrial thrombus in chronic nonrheumatic atrial fibrillation. Jpn. Heart J. 44, 481-491 2(003).
22. Marin F, Roldan V, Lip GY. Fibrinolytic function and atrial fibrillation. Thromb. Res. 109, 233-240 (2003).
23. Uno M, Tsuji H, Sawada S, Toyoda T, Nakagawa M. Fibrinopeptide A (FPA) levels in atrial fibrillation and the effects of heparin administration. Jpn. Circ. J. 52, 9-12 (1988).
24. Wang J, Xie X, He H, Huang J, Lu D, Yang Q. Hypercoagulability existing in the local left atrium of patient with mitral stenosis. Chin. Med. J. (Engl.). 116, 1198-1202 (2003).
25. Arakawa M, Miwa H, Kambara K et al. Changes in plasma concentrations of atrial natriuretic peptides after cardioversion of chronic atrial fibrillation. Am. J. Cardiol. 70, 550-552 (1992).
26. Cai H, Li Z, Goette A et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106, 2854-2858 (2002).
27. Minamino T, Kitakaze M, Sato H et al. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler. Thromb. Vasc. Biol. 17, 3191-3195 (1997).
28. Noris M, Morigi M, Donadelli R et al. Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. Circ. Res. 76, 536-543 (1995).
29. Rubart M, Zipes DP. NO hope for patients with atrial fibrillation. Circulation 106, 2764-2766 (2002).
30. No authors listed. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N. Engl. J. Med. 323, 1505-1511 (1990).
31. No authors listed. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 84, 527-539 (1991).
32. No authors listed. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342, 1255-1262 (1993).
33. No authors listed. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343, 687-691 (1994).
34. No authors listed. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154, 1449-1457 (1994).
35. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285, 2864-2870 (2001).
36. Hart RG, Halperin JL, Pearce LA et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann. Intern. Med. 138, 831-838 (2003).
37. Taylor FC, Cohen H, Ebrahim S. Systematic review of long-term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 322, 321-326 (2001).
38. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347, 1834-1840 (2002).
39. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347, 1825-1833 (2002).
40. Nixdorff U. Antithrombotic strategies for the management of non-valvular atrial fibrillation. Int. J. Cardiol. 100, 191-198 (2005).
41. Zeuthen EL, Lassen JF, Husted SE. Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation? Thromb. Res. 109, 241-246 (2003).
42. Reynolds MW, Fahrbach K, Hauch O et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 126, 1938-1945 (2004).
43. Cundiff DK. Anticoagulants for nonvalvular atrial fibrillation (NVAF)-drug review. MedGenMed. 5, 4 (2003).
44. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N. Engl. J. Med. 349, 675-683 (2003).
45. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch. Intern. Med. 160, 41-46 (2000).
46. Bungard TJ, Ghali WA, McAlister FA et al. The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can. J. Cardiol. 19, 280-284 (2003).
47. Gross CP, Vogel EW, Dhond AJ et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin. Ther. 25, 1750-1764 (2003).
48. Mayet J, Wasan B, Sutton GC. Cardioversion of atrial arrhythmias: audit of anticoagulation management. J. R. Coll. Physicians Lond. 31, 313-316 (1997).
49. Leung CS, Tam KM. Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong. Hong Kong Med. J. 9, 179-185 (2003).
50. Keaton C, Hirsh J. Management of anticoagulation before and after elective surgery. N. Engl. J. Med. 336, 1506-1511 (1997).
51. Wiegand UK, LeJeune D, Boguschewski F et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 126, 1177-1186 (2004).
52. Camm AJ. Atrial fibrillation: is there a role for low-molecular-weight heparin? Clin. Cardiol. 24, I15-I19 (2001).
53. Wodlinger AM, Pieper JA. Low-molecular-weight heparin in transesophageal echocardiography-guided cardioversion of atrial fibrillation. Pharmacotherapy 23, 57-63 (2003).
54. Murray RD, Shah A, Jasper SE et al. Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study. Am. Heart J. 139, 1-7 (2000).
55. Kovacs MJ, Keaton C, Rodger M et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 110, 1658-1663 (2004).
56. Akdeniz B, Turker S, Ozturk V et al. Cardioversion under the guidance of transesophageal echochardiograhy in persistent atrial fibrillation: results with low molecular weight heparin. Int. J. Cardiol. 98, 49-55 (2005).
57. de Luca I, Sorino M, Del Salvatore B, de Luca L. A new therapeutic strategy for electrical cardioversion of atrial fibrillation. Ital. Heart J. 2, 831-480 (2001).
58. Stellbrink C, Nixdorff U, Hofmann T et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 109, 997-1003 (2004).
59. Bechtold H, Gunzenhauser D, Sawitzki H, Fung S, Janssen D. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion. Z. Kardiol. 92, 532-539 (2003).
60. Yigit Z, Kucukoglu MS, Okcun B, Sansoy V, Guzelsoy D. The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation. Jpn. Heart J. 44, 369-377 (2003).
61. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch. Intern. Med. 164, 1319-1326 (2004).
62. Zeuthen EL, Lassen JF, Husted SE. Haemostatic activity in patients with atrial fibrillation treated with low-molecular-weight heparin before and after electrical cardioversion. J. Thromb. Thrombolysis. 17, 185-189 (2004).
63. Sarich TC, Wolzt M, Eriksson UG et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J. Am. Coll. Cardiol. 41, 557-564 (2003).
64. Eriksson UG, Bredberg U, Hoffmann KJ et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab. Dispos. 31, 294-305 (2003).
65. Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin. Hematol. 39, 187-196 (2002).
66. Hopfner R. Ximelagatran (AstraZeneca). Curr. Opin. Investig. Drugs 3, 246-251 (2002).
67. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J. Intern. Med. 254, 322-334 (2003).
68. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb. Res. 109, S9-S15 (2003).
69. Gustafsson D, Antonsson T, Bylund R et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemost. 79, 110-118 (1998).
70. Nylander S, Mattsson C. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood Coagul. Fibrinolysis 14, 159-167 (2003).
71. Mattsson C, Menschik-Lundin A, Nylander S, Gyzander E, Deinum J. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro. Thromb. Res. 104, 475-486 (2001).
72. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J. Am. Coll. Cardiol. 41, 1445-1451 (2003).
73. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362, 1691-1698 (2003).
74. Albers GW, Diener HC, Frison L et al. Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293, 690-698 (2005).
75. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 293, 699-706 (2005).
76. Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation 110, I19-I26 (2004).
77. Edvardsson N, Juul-Moller S, Omblus R, Pehrsson K. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J. Intern. Med. 254, 95-101 (2003).
78. Gullov AL, Koefoed BG, Petersen P et al. Fixed minidose warfarin and aspirin alone and in combination vs. adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch. Intern. Med. 158, 1513-1521 (1998).
79. No authors listed. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348, 633-638 (1996).
80. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 131, 492-501 (1999).
81. Perez-Gomez F, Alegria E, Berjon J et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J. Am. Coll. Cardiol. 44, 1557-1566 (2004).
82. Sievert H, Lesh MD, Trepels T et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 105, 1887-1889 (2002).
83. Crystal E, Lamy A. Connolly SJ et al. Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. Am. Heart J. 145, 174-178 (2003).
84. Nakai T, Lesh MD, Gerstenfeld EP, Virmani R, Jones R, Lee RJ. Percutaneous left atrial appendage occlusion (PLAATO) for preventing cardioembolism: first experience in canine model. Circulation 105, 2217-2222 (2002).
85. Meier B, Palacios I, Windecker S et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc. Interv. 60, 417-422 (2003).
86. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: clinical applications. JAMA 288, 1396-1398 (2002).
87. Lown B, Perlroth M, Kaidbey S, Tadaaki A, Harkin D. Cardioversion of atrial fibrillation. N. Engl. J. Med. 269, 325-331 (1963).
88. Lown B. Electrical reversion of cardiac arrhythmias. Br. Heart J. 29, 469-489 (1967).
89. Resnekov L, McDonald L. Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion. Br. Heart J. 29, 926-936 (1967).
90. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am. J. Cardiol. 23, 208-216 (1969).
91. Lown B, Kleiger R, Williams J. Cardioversion and digitalis drugs: changed threshold to electric shock in digitalized animals. Circ. Res. 17, 519-531 (1965).
92. Carlsson J, Tebbe U, Rox J et al. Cardioversion of atrial fibrillation in the elderly. ALKK-Study Group. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausaerzte. Am. J. Cardiol. 78, 1380-1384 (1996).
93. Botkin SB, Dhanekula LS, Olshansky B. Out-patient cardioversion of atrial arrhythmias: efficacy, safety, and costs. Am. Heart J. 145, 233-238 (2003).
94. Gallagher MM, Hennessy BJ, Edvardsson N et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J. Am. Coll. Cardiol. 40, 926-933 (2002).
95. Olshansky B, Rosenfeld LE, Warner AL et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J. Am. Coll. Cardiol. 43, 1201-1208 (2004).
96. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356, 1789-1794 (2000).
97. Aberg H, Cullhed I. Direct current countershock complications. Acta Med. Scand. 183, 415-4 21 (1968).
98. Jacoby JL, Cesta M, Heller MB, Salen P, Reed J. Synchronized emergency department cardioversion of atrial dysrhythmias saves time, money and resources. J. Emerg. Med. 28, 27-30 (2005).
99. Burton JH, Vinson DR, Drummond K, Strout TD, Thode HC, McInturff JJ. Electrical cardioversion of emergency department patients with atrial fibrillation. Ann. Emerg Med. 44, 20-30 (2004).
100. Li H, Riedel R, Oldemeyer JB, Rovang K, Hee T. Comparison of recurrence rates after direct-current cardioversion for new-onset atrial fibrillation in patients receiving versus those not receiving rhythm-control drug therapy. Am. J. Cardiol. 93, 45-48 (2004).
101. Domanovits H, Schillinger M, Thoennissen J et al. Termination of recent-onset atrial fibrillation/flutter in the emergency department: a sequential approach with intravenous ibutilide and external electrical cardioversion. Resuscitation 45, 181-187 (2000).
102. Przybylski A, Sterlinski M, Lewandowski M et al. Risk of thromboembolic complications in patients with permanent atrial fibrillation undergoing cardioverter-defibrillator implantation. Kardiol. Pol. 57, 306-312 (2002).
103. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am. J. Cardiol. 82, 1545-1547 (1998).
104. Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J. Am. Coll. Cardiol. 31, 588-592 (1998).
105. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Coll. Cardiol. 35, 183-187 (2000).
106. No authors listed. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348, 633-638 (1996).
107. Nakajima K, Ichinose M. Ischemic stroke in elderly patients with paroxysmal atrial fibrillation. Nippon Ronen Igakkai Zasshi 33, 273-277 (1996).
108. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham Study. Am. Heart J. 106, 389-396 (1983).
109. Treseder AS, Sastry BS, Thomas TP, Yates MA, Pathy MS. Atrial fibrillation and stroke in elderly hospitalized patients. Age Ageing 15, 89-92 (1986).
110. Cabin HS, Clubb KS, Hall C, Perlmutter RA, Feinstein AR. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am. J. Cardiol. 65, 1112-1116 (1990).
111. Ellenbogen KA, Stambler BS, Wood MA et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J. Am. Coll. Cardiol. 28, 130-136 (1996).
112. Singh S, Zoble RG, Yellen L et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102, 2385-9230 (2000).
113. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 94, 1613-1621 (1996).
114. Oral H, Souza JJ, Michaud GF et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N. Engl. J. Med. 340, 1849-1854 (1999).
115. Volgman AS, Carberry PA, Stambler B et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J. Am. Coll. Cardiol. 31, 1414-1419 (1998).
116. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 104, 292-296 (2001).
117. Bianconi L, Castro A, Dinelli M et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur. Heart J. 21, 1265-1273 (2000).
118. Glatter K, Yang Y, Chatterjee K et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 103, 253-257 (2001).
119. Zhang Y, Ramabadran RS, Boddicker KA et al. Triphasic waveforms are superior to biphasic waveforms for transthoracic defibrillation: experimental studies. J. Am. Coll. Cardiol. 42, 568-575 (2003).
120. Zhang Y, Rhee BJ, Davies LR, Kerber RE. Quadraphasic shocks for transthoracic defibrillation: experimental studies. Circulation 108, 319 (2003).
121. Carunchio A, Burattini M, Coletta C et al. Electrical cardioversion for atrial fibrillation: advantages of the transthoracic biphasic method. Ital. Heart J. 3, 638-645 (2002).
122. Ermis C, Zhu AX, Sinha S et al. Efficacy of biphasic waveform cardioversion for atrial fibrillation and atrial flutter compared with conventional monophasic waveforms. Am. J. Cardiol. 90, 891-892 (2002).
123. Havranek E. Biphasic waveform shocks were effective and efficient for cardioversion of atrial fibrillation. ACP J. Club. 138, 8 (2003).
124. Khaykin Y, Newman D, Kowalewski M, Korley V, Dorian P. Biphasic versus monophasic cardioversion in shock-resistant atrial fibrillation. J. Cardiovasc. Electrophysiol. 14, 868-872 (2003).
125. Marinsek M, Larkin GL, Zohar P et al. Efficacy and impact of monophasic versus biphasic countershocks for transthoracic cardioversion of persistent atrial fibrillation. Am. J. Cardiol. 92, 988-991 (2003).
126. Neal S, Ngarmukos T, Lessard D, Rosenthal L. Comparison of the efficacy and safety of two biphasic defibrillator waveforms for the conversion of atrial fibrillation to sinus rhythm. Am. J. Cardiol. 92, 810-814 (2003).
127. Neri G, Alitto F, Zamprogno R et al. Efficacy and safety of ambulatory electric cardioversion of atrial fibrillation with monophasic and biphasic shock. Ital. Heart J. 2, 1315-1318 (2001).
128. Page RL, Kerber RE, Russell JK et al. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J. Am. Coll. Cardiol. 39, 1956-1963 (2002).
129. Scholten M, Szili-Torok T, Klootwijk P, Jordaens L. Comparison of monophasic and biphasic shocks for transthoracic cardioversion of atrial fibrillation. Heart 89, 1032-1034 (2003).
130. Mittal S, Ayati S, Stein KM et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 101, 1282-1287 (2000).
131. Kerber RE. Transthoracic cardioversion of atrial fibrillation and flutter: standard techniques and new advances. Am. J. Cardiol. 78, 22-26 (1996).
132. Cooper JM, Katcher MS, Orlov MV. Implantable devices for the treatment of atrial fibrillation. N. Engl. J. Med. 346, 2062-2068 (2002).
133. Wellens HJ, Lau CP, Luderitz B et al. Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation 98, 1651-1656 (1998).
134. Omran H, Jung W, Rabahieh R et al. Left atrial chamber and appendage function after internal atrial defibrillation: a prospective and serial transesophageal echocardiographic study. J. Am. Coll. Cardiol. 29, 131-138 (1997).
135. Tse HF, Lau CP. Bleeding and thromboembolic risks of internal cardioversion for persistent atrial fibrillation. Pacing Clin. Electrophysiol. 25, 1752-1755 (2002).
136. Maria Amuchastegui L, Cravero C, Salomone O, Amuchastegui M. Atrial mechanical function before and after electrical or amiodarone cardioversion in atrial fibrillation: assessment by transesophageal echocardiography and pulsed Doppler. Echocardiography 13, 123-130 (1996).
137. van Walraven C, Hart RG, Singer DE et al. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288, 2441-2448 (2002).
138. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349, 1019-1026 (2003).
139. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J. Am. Coll. Cardiol. 19, 851-855 (1992).
140. Elhendy A, Gentile F, Khandheria BK, Bailey KR, Burger KN, Seward JB. Safety of electrical cardioversion in patients with previous embolic events. Mayo Clin. Proc. 76, 364-368 (2001).
141. Elhendy A, Gentile F, Khandheria BK et al. Thromboembolic complications after electrical cardioversion in patients with atrial flutter. Am. J. Med. 111, 433-438 (2001).
142. Gentile F, Elhendy A, Khandheria BK et al. Safety of electrical cardioversion in patients with atrial fibrillation. Mayo Clin. Proc. 77, 897-904 (2002).
143. Lanzarotti CJ, Olshansky B. Thromboembolism in chronic atrial flutter: is the risk underestimated? J. Am. Coll. Cardiol. 30, 1506-1511 (1997).
144. Mehta D, Baruch L. Thromboembolism following cardioversion of 'common' atrial flutter. Risk factors and limitations of transesophageal echocardiography Chest 110, 1001-1003 (1996).
145. Seidl K, Hauer B, Schwick NG, Zellner D, Zahn R, Senges J. Risk of thromboembolic events in patients with atrial flutter. Am. J. Cardiol. 82, 580-583 (1998).
146. Sherman DG, Kim SG, Boop BS et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch. Intern. Med. 165, 1185-1191 (2005).
147. Wyse DG. The AFFIRM trial: main trial and substudies - what can we expect? J. Interv. Card. Electrophysiol. 4(Suppl. 1), 171-176 (2000).
148. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347, 1834-1840 (2002).
149. Fetsch T, Burschel G, Breithardt G et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study. Z. Kardiol. 88, 195-207 (1999).
150. Ferguson JJ III. Meeting Highlights: Highlights of the XXIII Congress of the European Society of Cardiology. Circulation 104, 111E-116E (2001).
151. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J. Am. Coll. Cardiol. 25, 452-459 (1995).
152. Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 h. Ann. Intern. Med. 126, 615-620 (1997).
153. Olshansky B, Wilber DJ, Hariman RJ. Atrial flutter - update on the mechanism and treatment. Pacing Clin. Electrophysiol. 15, 2308-2335 (1992).
154. Prater S, Reynertson S, Louie E, Hariman RJ, Olshansky B. Incidence of atrial thrombus in patients with Type I atrial flutter undergoing catheter ablation. Circulation 94, 728 (1996).
155. Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA. Risk of stroke in patients with atrial flutter. Am. J. Cardiol. 87, 346-349 (2001).
156. Liaudet L, Kehtari R, Enrico JF. Cerebral thromboembolism after direct current cardioversion for pure atrial flutter. Intensive Care Med. 23, 196-197 (1997).
157. Bikkina M, Alpert MA, Mulekar M, Shakoor A, Massey CV, Covin FA. Prevalence of intraatrial thrombus in patients with atrial flutter. Am. J. Cardiol. 76, 186-189 (1995).
158. Irani WN, Grayburn PA, Afridi I. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter. A prospective study using transesophageal echocardiography. Circulation 95, 962-966 (1997).
159. Jordaens L, Missault L, Germonpre E et al. Delayed restoration of atrial function after conversion of atrial flutter by pacing or electrical cardioversion. Am. J. Cardiol. 71, 63-67 (1993).
160. Wadas MA, Prater S, Martini M et al. Left atrial appendage contraction velocities are neither regular frequency nor uniform in amplitude despite apparently well organized electric activation in atrial flutter. J. Am. Coll. Cardiol. 29, 291A (1997).
161. Corrado G, Sgalambro A, Mantero A et al. Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Societa Italiana di Ecografia Cardiovascolare) multicentre study. Eur. Heart J. 22, 1042-1051 (2001).
162. Kaneko K, Hirono O, Fatema K et al. Direct evidence that sustained dysfunction of left atrial appendage contributes to the occurrence of cardiogenic brain embolism in patients with paroxysmal atrial fibrillation. Intern. Med. 42, 1077-1083 (2003).
163. Sakurai K, Hirai T, Nakagawa K et al. Left atrial appendage function and abnormal hypercoagulability in patients with atrial flutter. Chest 124, 1670-1674 (2003).
164. Ito T, Suwa M, Nakamura T, Miyazaki S, Kobashi A, Kitaura Y. Quantification of left atrial appendage spontaneous echo contrast in patients with chronic nonalvular atrial fibrillation. J. Cardiol. 37, 325-333 (2001).
165. Black IW. Spontaneous echo contrast: where there's smoke there's fire. Echocardiography 17, 373-382 (2000).
166. Fonseca N, Caetano F, Santos J et al. Transesophageal echocardiography-guided cardioversion of atrial fibrillation. Selection of a low-risk group for immediate cardioversion. Rev. Port.
167. Klein AL, Grimm RA, Murray RD et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N. Engl. J. Med. 344, 1411-1420 (2001).
168. Kamalesh M, Subbiah S, Sharan L, Tawam M, Sawada S. Rapid formation of left atrial appendage thrombus after unsuccessful cardioversion of atrial fibrillation. Echocardiography 18, 157-158 (2001).
169. Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J. Am. Coll. Cardiol. 37, 691-704 (2001).
170. Stollberger C, Schneider B, Finsterer J. Is percutaneous left atrial appendage transcatheter occlusion an alternative to oral anticoagulation in patients with atrial fibrillation? Circulation 107, E11-E12 (2003).
171. Manning WJ, Silverman DI, Douglas PS. Thromboembolism after negative TEE. Circulation 90, 3121-3122 (1994).
172. Missault L, Jordaens L, Gheeraert P, Adang L, Clement D. Embolic stroke after unanticoagulated cardioversion despite prior exclusion of atrial thrombi by transoesophageal echocardiography Eur. Heart J. 15, 1279-1280 (1994).
173. Seidl K, Rameken M, Drogemuller A et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study. J. Am. Coll. Cardiol. 39, 1436-1442 (2002).
174. Black IW, Fatkin D, Sagar KB et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation 89, 2509-2513 (1994).
175. Achenbach S, Sacher D, Ropers D et al. Electron beam computed tomography for the detection of left atrial thrombi in patients with atrial fibrillation. Heart 90, 1477-1478 (2004).
176. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 108, 1871-1909 (2003).
177. Rotmensch HH, Rotmensch S, Elkayam U. Management of cardiac arrhythmias during pregnancy. Current concepts. Drugs 33, 623-633 (1987).
178. Ueland K, McAnulty H, Ueland FR, Metcalfe J. Special considerations in the use of cardiovascular drugs Clin. Obstet. Gynecol. 24, 809-823 (1981).
179. Ogburn PL Jr, Schmidt G, Linman J, Cefalo RC. Paroxysmal tachycardia and cardioversion during pregnancy. J. Reprod. Med. 27, 359-362 (1982).
180. Treakle K, Kostic B, Hulkower S. Supraventricular tachycardia resistant to treatment in a pregnant woman. J. Fam. Pract. 35, 581-584 (1992).
181. Gowda RM, Khan IA, Mehta NJ, Vasavada BC, Sacchi TJ. Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations. Int. J. Cardiol. 88, 129-133 (2003).
182. Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf. 20, 85-94 (1999).
183. Page RL. Treatment of arrhythmias during pregnancy. Am. Heart J. 130, 871-876 (1995).
184. Pahlow B, Geisler AK, Davis GH. Management of acute paroxysmal supraventricular tachycardia in pregnancy. J. Am. Osteopath. Assoc. 91, 51-52, 57, 61-62 (1991).
185. Rosemond RL. Cardioversion during pregnancy. JAMA 269, 3167 (1993).
186. Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG 109, 1406-1407 (2002).
187. Gronefeld GC, Mauss O, Li YG, Klingenheben T, Hohnloser SH. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study. J. Cardiovasc. Electrophysiol. 11, 1208-1214 (2000).
188. Welch PJ, Afridi I, Joglar JA et al. Effect of radiofrequency ablation on atrial mechanical function in patients with atrial flutter. Am. J. Cardiol. 84, 420-425 (1999).
189. Takami M, Suzuki M, Sugi K, Ikeda T. Time course for resolution of left atrial appendage stunning after catheter ablation of chronic atrial flutter. J. Am. Coll. Cardiol. 41, 2207-2211 (2003).